A Nanobody Targeting Carcinoembryonic Antigen As a Promising Molecular Probe for Non-small Cell Lung Cancer

Overview

Journal Mol Med Rep

Specialty Molecular Biology

Date 2017 Jun 7

PMID 28586008

Citations 13

Authors

Hao Wang

Ai-Min Meng

Sheng-Hua Li

Xiao-Liang Zhou

Affiliations

Soon will be listed here.

Abstract

Carcinoembryonic antigen (CEA) is a biomarker and therapy target for non‑small cell lung cancer (NSCLC), which is the most common type of lung cancer. Nanobodies with high target specificity are promising candidates to function as anti‑CEA probes. In the present study, the targeting effects of an anti‑CEA nanobody obtained from phage display were investigated using technetium‑99 m (99mTc) and fluorescence labeling. In vitro binding and immunofluorescent staining assays, as well as in vivo blood clearance and biodistribution assays were performed. High specificity and affinity of the nanobody for CEA‑positive H460 cells was observed in vitro. The pharmacokinetics assay of the 99mTc‑nanobody in Wistar rats demonstrated that the nanobody had appropriate T1/2α and T1/2β, which were 20.2 and 143.5 min, respectively. The biodistribution assay using H460 xenograft‑bearing nude mice demonstrated a high ratio of signal in tumor compared with background, which confirmed that the nanobody may be useful as a molecular probe for CEA‑positive cancer, particularly in NSCLC.

Citing Articles

Carcinoembryonic Antigen CEA - Prognostic Value in Immediate Post-Operative Mortality in Colorectal Cancer.

Firut A, Scurtu S, Schenker M, Gadea N, Patrascu A, Padureanu V Curr Health Sci J. 2024; 49(4):579-583.

PMID: 38559837 PMC: 10976198. DOI: 10.12865/CHSJ.49.04.14.

Promising Diagnostic and Therapeutic Approaches Based on VHHs for Cancer Management.

Cong Y, Devoogdt N, Lambin P, Dubois L, Yaromina A Cancers (Basel). 2024; 16(2).

PMID: 38254860 PMC: 10814765. DOI: 10.3390/cancers16020371.

Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga]Ga-nanobody: from bench to bedside.

Li L, Lin X, Wang L, Ma X, Zeng Z, Liu F Eur J Nucl Med Mol Imaging. 2023; 50(12):3735-3749.

PMID: 37382662 DOI: 10.1007/s00259-023-06313-1.

Radionuclide-based theranostics - a promising strategy for lung cancer.

Zhu T, Hsu J, Guo J, Chen W, Cai W, Wang K Eur J Nucl Med Mol Imaging. 2023; 50(8):2353-2374.

PMID: 36929181 PMC: 10272099. DOI: 10.1007/s00259-023-06174-8.

Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment.

Wang J, Kang G, Yuan H, Cao X, Huang H, de Marco A Front Immunol. 2022; 12:838082.

PMID: 35116045 PMC: 8804282. DOI: 10.3389/fimmu.2021.838082.

References

Koppe M, Bleichrodt R, Soede A, Verhofstad A, Goldenberg D, Oyen W . Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J Nucl Med. 2004; 45(7):1224-32. View

Olafsen T, Wu A . Antibody vectors for imaging. Semin Nucl Med. 2010; 40(3):167-81. PMC: 2853948. DOI: 10.1053/j.semnuclmed.2009.12.005. View

Bell A, Wang Z, Arbabi-Ghahroudi M, Chang T, Durocher Y, Trojahn U . Differential tumor-targeting abilities of three single-domain antibody formats. Cancer Lett. 2009; 289(1):81-90. DOI: 10.1016/j.canlet.2009.08.003. View

Wu W, Li S, Zhang W, Sun J, Ren G, Dong Q . A novel VHH antibody targeting the B cell-activating factor for B-cell lymphoma. Int J Mol Sci. 2014; 15(6):9481-96. PMC: 4100105. DOI: 10.3390/ijms15069481. View

Grunnet M, Sorensen J . Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2011; 76(2):138-43. DOI: 10.1016/j.lungcan.2011.11.012. View

DAS A, Barik S, Banerjee S, Bose A, Sarkar K, Biswas J . A monoclonal antibody against neem leaf glycoprotein recognizes carcinoembryonic antigen (CEA) and restricts CEA expressing tumor growth. J Immunother. 2014; 37(8):394-406. DOI: 10.1097/CJI.0000000000000050. View

Aerts A, Impens N, Gijs M, DHuyvetter M, Vanmarcke H, Ponsard B . Biological carrier molecules of radiopharmaceuticals for molecular cancer imaging and targeted cancer therapy. Curr Pharm Des. 2014; 20(32):5218-44. DOI: 10.2174/1381612819666140110114902. View

Dai H, Liu J, Liang L, Ban C, Jiang J, Liu Y . Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers. Respirology. 2014; 19(5):707-13. DOI: 10.1111/resp.12317. View

Conaghan P, Ashraf S, Tytherleigh M, Wilding J, Tchilian E, Bicknell D . Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen. Br J Cancer. 2008; 98(7):1217-25. PMC: 2359646. DOI: 10.1038/sj.bjc.6604289. View

10.

Siontorou C . Nanobodies as novel agents for disease diagnosis and therapy. Int J Nanomedicine. 2013; 8:4215-27. PMC: 3818023. DOI: 10.2147/IJN.S39428. View

11.

Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T . Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer. Anticancer Res. 2010; 30(7):3099-102. View

12.

Gold P, Freedman S . DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES. J Exp Med. 1965; 121:439-62. PMC: 2137957. DOI: 10.1084/jem.121.3.439. View

13.

Jeon B, Shin R, Chung J, Jung I, Heo S . Individualized Cutoff Value of the Preoperative Carcinoembryonic Antigen Level is Necessary for Optimal Use as a Prognostic Marker. Ann Coloproctol. 2013; 29(3):106-14. PMC: 3710771. DOI: 10.3393/ac.2013.29.3.106. View

14.

Yang K, Yang S, Liang W, Kuo Y, Lin J, Lin T . Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery. Radiat Oncol. 2013; 8:43. PMC: 3599903. DOI: 10.1186/1748-717X-8-43. View

15.

Wahl R, Philpott G, Parker C . Monoclonal antibody radioimmunodetection of human-derived colon cancer. Invest Radiol. 1983; 18(1):58-62. DOI: 10.1097/00004424-198301000-00010. View

16.

Desmyter A, Decanniere K, Muyldermans S, Wyns L . Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. J Biol Chem. 2001; 276(28):26285-90. DOI: 10.1074/jbc.M102107200. View

17.

Ghosh I, Bhattacharjee D, Kumar Das A, Chakrabarti G, Dasgupta A, Dey S . Diagnostic Role of Tumour Markers CEA, CA15-3, CA19-9 and CA125 in Lung Cancer. Indian J Clin Biochem. 2014; 28(1):24-9. PMC: 3547445. DOI: 10.1007/s12291-012-0257-0. View

18.

KRUPEY J, Gold P, Freedman S . Purification and characterization of carcinoembryonic antigens of the human digestive system. Nature. 1967; 215(5096):67-8. DOI: 10.1038/215067a0. View

19.

Gainkam L, Huang L, Caveliers V, Keyaerts M, Hernot S, Vaneycken I . Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med. 2008; 49(5):788-95. DOI: 10.2967/jnumed.107.048538. View

20.

Liu G, Liu X, Lv X, Wang X, Fang X, Sang Y . miR-148b functions as a tumor suppressor in non-small cell lung cancer by targeting carcinoembryonic antigen (CEA). Int J Clin Exp Med. 2014; 7(8):1990-9. PMC: 4161539. View